
1. travel med infect dis. 2015 jan-feb;13(1):89-93. doi:
10.1016/j.tmaid.2014.12.010. epub 2014 dec 31.

failure atovaquone-proguanil malaria chemoprophylaxis traveler ghana.

boggild ak(1), lau r(2), reynaud d(3), kain kc(4), gerson m(5).

author information: 
(1)tropical disease unit, division infectious diseases, university health
network-toronto general hospital, toronto, canada; department medicine,
university toronto, toronto, canada; public health ontario laboratories,
public health ontario, toronto, canada. electronic address:
andrea.boggild@utoronto.ca.
(2)public health ontario laboratories, public health ontario, toronto, canada.
(3)the centre study complex childhood diseases, hospital sick
children, toronto, ontario, canada.
(4)tropical disease unit, division infectious diseases, university health
network-toronto general hospital, toronto, canada; department medicine,
university toronto, toronto, canada; sandra a. rotman laboratories, sandra
rotman centre global health, university toronto, canada.
(5)humber river hospital, north york, canada.

clinical failure malarone™ chemoprophylaxis extremely rare. report a
case plasmodium falciparum malaria returned traveler ghana fully
adhered atovaquone-proguanil (malarone™) chemoprophylaxis daily dosing, yet
took pills empty stomach. screening p. falciparum isolate
revealed triple codon mutation dhfr positions 51, 59, 108. plasma drug 
levels atovaquone proguanil revealed sub-therapeutic concentrations.

copyright © 2014 elsevier ltd. rights reserved.

doi: 10.1016/j.tmaid.2014.12.010 
pmid: 25582377  [indexed medline]

